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ABSTRACT
OBJECTIVE
To investigate the cardiovascular effectiveness of 
sodium glucose cotransporter 2 (SGLT2) inhibitors in 
routine clinical practice.
DESIGN
Cohort study using data from nationwide registers and 
an active-comparator new-user design.
SETTING
Denmark, Norway, and Sweden, from April 2013 to 
December 2016.
PARTICIPANTS
20 983 new users of SGLT2 inhibitors and 20 983 new 
users of dipeptidyl peptidase 4 (DPP4) inhibitors, 
aged 35-84, matched by age, sex, history of major 
cardiovascular disease, and propensity score.
MAIN OUTCOME MEASURES
Primary outcomes were major cardiovascular events 
(composite of myocardial infarction, stroke, and 
cardiovascular death) and heart failure (hospital 
admission for heart failure or death due to heart 
failure). Secondary outcomes were the individual 
components of the cardiovascular composite and any 
cause death. In the primary analyses, patients were 
defined as exposed from treatment start throughout 
follow-up (analogous to intention to treat); additional 
analyses were conducted with an as-treated exposure 
definition. Cox regression was used to estimate hazard 
ratios.
RESULTS
Mean age of the study cohort was 61 years, 60% were 
men, and 19% had a history of major cardiovascular 
disease. Of the total 27 416 person years of follow-up 
in the SGLT2 inhibitor group, 22 627 (83%) was among 
patients who initiated dapagliflozin, 4521 (16%) 
among those who initiated empagliflozin, and 268 
(1%) among those who initiated canagliflozin. During 
follow-up, 467 SGLT2 inhibitor users (incidence rate 
17.0 events per 1000 person years) and 662 DPP4 
inhibitor users (18.0) had a major cardiovascular 
event, whereas 130 (4.7) and 265 (7.1) had a heart 
failure event, respectively. Hazard ratios were 0.94 
(95% confidence interval 0.84 to 1.06) for major 
cardiovascular events and 0.66 (0.53 to 0.81) for 
heart failure. Hazard ratios were consistent among 
subgroups of patients with and without history of 
major cardiovascular disease and with and without 
history of heart failure. Hazard ratios for secondary 
outcomes, comparing SGLT2 inhibitors with DPP4 
inhibitors, were 0.99 (0.85 to 1.17) for myocardial 
infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 
1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) 
for any cause death. In the as-treated analyses, hazard 
ratios were 0.84 (0.72 to 0.98) for major cardiovascular 
events, 0.55 (0.42 to 0.73) for heart failure, 0.93 (0.76 
to 1.14) for myocardial infarction, 0.83 (0.64 to 1.07) 
for stroke, 0.67 (0.49 to 0.93) for cardiovascular death, 
and 0.75 (0.61 to 0.91) for any cause death.
CONCLUSIONS
 In this large Scandinavian cohort, SGLT2 inhibitor use 
compared with DPP4 inhibitor use was associated 
with reduced risk of heart failure and any cause 
death, but not with major cardiovascular events in the 
primary intention-to-treat analysis. In the additional 
as-treated analyses, the magnitude of the association 
with heart failure and any cause death became larger, 
and a reduced risk of major cardiovascular events 
that was largely driven by the cardiovascular death 
component was observed. These data help inform 
patients, practitioners, and authorities regarding the 
cardiovascular effectiveness of SGLT2 inhibitors in 
routine clinical practice.
Introduction
Sodium glucose cotransporter 2 (SGLT2) inhibitors 
are relatively new glucose lowering drugs used 
in the treatment of type 2 diabetes. Randomised 
placebo controlled trials of cardiovascular outcomes, 
conducted in patients with type 2 diabetes with 
a history of cardiovascular disease or who were 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Data from randomised cardiovascular outcome trials have shown that 
sodium glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major 
cardiovascular events and heart failure among patients with type 2 diabetes who 
have established cardiovascular disease or are at high cardiovascular risk
The cardiovascular effectiveness of SGLT2 inhibitors in routine clinical practice is 
unclear
WHAT THIS STUDY ADDS
In this large cohort study based on nationwide data from three Scandinavian 
countries, use of SGLT2 inhibitors, as compared with use of dipeptidyl peptidase 
4 (DPP4) inhibitors, was associated with a 34% reduced risk of heart failure but 
was not associated with a reduced risk of major cardiovascular events
Use of SGLT2 inhibitors was also associated with a 20% reduced risk of any 
cause death
The findings were consistent in patients with and without history of major 
cardiovascular disease
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otherwise at high cardiovascular risk, have shown that 
these drugs (including canagliflozin, dapagliflozin, and 
empagliflozin) reduce the risk of hard cardiovascular 
endpoints.1-3 A recent meta-analysis of these trials 
showed that SGLT2 inhibitors reduced major adverse 
cardiovascular events (the composite of myocardial 
infarction, stroke, and cardiovascular death; hazard 
ratio 0.89, 95% confidence interval 0.83 to 0.96)), 
hospital admission for heart failure (0.69, 0.61 to 
0.79), and any cause death (0.85, 0.78 to 0.93), 
although heterogeneity was high for the any cause 
death outcome across the three trials.4
Although these data, derived from controlled trial 
settings, provide firm evidence for the cardiovascular 
efficacy of SGLT2 inhibitors among patients at 
high cardiovascular risk, complementary data are 
needed to understand to what extent they translate 
to cardiovascular effectiveness in the broad group 
of patients in routine clinical practice. A few 
observational studies of SGLT2 inhibitors have been 
published. However, these studies were focused 
on heart failure alone,5 6 or used designs6-11 that 
introduced immortal time, which has a strong potential 
for bias towards protective associations in favour of 
SGLT2 inhibitors.12 w13 One well designed study, which 
investigated canagliflozin alone, reported a reduced 
risk of hospital admission for heart failure versus 
three other glucose lowering drugs, but no difference 
in risk of a composite of myocardial infarction or 
stroke (cardiovascular death was not included in 
this composite).14 However, that study did not have 
adequate data on causes of death or on total mortality, 
and was thus unable to investigate cardiovascular and 
any cause death.
In this register based cohort study, we used 
nationwide data from three Scandinavian countries 
to investigate the risk of major cardiovascular events 
and heart failure among new users of SGLT2 inhibitors 
versus an active comparator drug class, dipeptidyl 
peptidase 4 (DPP4) inhibitors.
Methods
Cohort
We conducted a cohort study, from April 2013 to 
December 2016, using nationwide register data 
from Denmark, Norway, and Sweden, and an active-
comparator new-user design. 15 All patients in the three 
countries, who were aged 35-84, and who were new 
users of either SGLT2 inhibitors or DPP4 inhibitors was 
eligible for inclusion. New use was defined as initiation 
of either drug class among patients with no use of either 
drug class within the past two years. Exclusion criteria 
were dialysis or renal transplantation, end stage illness, 
drug misuse, major pancreatic disease, no prescription 
drug or register entry in the national patient registers 
in the past year, and hospital admission for any cause 
in the past 30 days (definitions in web table 1).
Data sources
Data were obtained from registers that have nationwide 
coverage of each of the three study countries and linked 
on individual level using unique patient identifiers. 
The data sources are summarised in web table 2 
and have been described in detail previously.16  17 
Briefly, drug treatment data were obtained from the 
national prescription registers, which record all filled 
prescriptions from all pharmacies in the countries, 
including information on specific drug, date of 
drug dispensing, and amount of drug. Given their 
nationwide coverage, these registers permitted the 
identification of all patients in the three countries 
initiating the study drugs. 
The population registers and the central bureaus 
of statistics provided demographic, vital status, and 
socioeconomic data. The national patient registers 
were used to obtain information on outcomes and 
comorbidities; these registers record all admissions to 
hospitals and outpatient specialist visits, and include 
data such as date of contact, diagnostic codes, and 
procedure codes. The cause of death registers, which 
are based on death certificates, provided cause of 
death data. The above data sources were used for the 
main analyses. For a sensitivity analysis, additional 
patient characteristics were obtained from the Swedish 
National Diabetes Register, a nationwide register to 
which trained physicians and nurses report clinical 
information regarding patients with diabetes.
Confounder control and matching
Propensity score methods were used to control for 59 
potential confounder variables, including demographic 
and socioeconomic factors, comorbidities, drug 
treatments, and healthcare use (web table 3). We 
estimated propensity scores using logistic regression. 
Three variables had missing values (country of birth 
(<1% missing), civil status (<1%), and education 
(3%)); we handled these values by using a missing 
value category.18 SGLT2 inhibitor and DPP4 inhibitor 
users were matched, country wise, in a 1:1 ratio on 
propensity score using the nearest neighbour matching 
algorithm (caliper width 0.2 of the standard deviation 
of the logit score) with sex, age (five year intervals), 
and history of major cardiovascular disease (web table 
4) as additional matching criteria. The analyses were 
conducted in a pooled, matched, three country cohort.
Outcomes
The coprimary outcomes were major cardiovascular 
events (defined as the composite of myocardial 
infarction, stroke, and cardiovascular death) and 
heart failure (defined as hospital admission for or 
death due to heart failure). Secondary outcomes were 
the components of the major cardiovascular events 
composite and any cause death. Cardiovascular 
outcomes were identified from primary diagnoses 
assigned during hospital admissions, captured through 
the national patient registers, and underlying cause 
of death diagnoses, captured through the cause of 
death registers (ICD-10 (international classification of 
diseases, 10th revision) codes in web table 5). The any 
cause death outcome was based on vital status data 
from the population registers. Scandinavian validation 
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studies have shown that a register based strategy for 
identification of cardiovascular outcomes has positive 
predictive values of 88-100% for myocardial infarction, 
69-99% for stroke, and 76-95% for heart failure (with 
the positive predictive values towards the higher ends 
of these ranges when validation assessments are 
based on primary diagnoses).19-21 As supplementary 
outcomes, we also analysed two serious adverse event 
outcomes of current concern with SGLT2 inhibitors: 
lower limb amputation and diabetic ketoacidosis 
(definitions in web table 5).2 16 22-24
Statistical analysis
Patients were followed from drug initiation to outcome 
event, emigration, death, age 85, or end of study. 
Patients were defined as exposed from treatment start 
throughout follow-up, analogous to an intention-to-
treat design. Cox proportional hazards regression, with 
time since start of treatment as the underlying time 
scale, was used to estimate hazard ratios. Absolute 
differences, expressed as events per 1000 person 
years, were calculated as hazard ratio−1 multiplied 
by the rate in the comparator group, with the 95% 
confidence interval calculated analogously. Results 
were considered statistically significant if the 95% 
confidence interval did not overlap 1.0. Analyses were 
conducted using SAS software (version 9.4).
We conducted subgroup analyses of both coprimary 
outcomes to assess effect modification by baseline 
characteristics, including analyses by sex, age, history 
of major cardiovascular disease (acute coronary 
syndrome, coronary revascularisation, stroke, heart 
failure, or peripheral arterial disease; definitions in 
web table 4), and history of heart failure (web table 
4). A Wald test for homogeneity was used to assess 
differences between subgroups, regarding P<0.05 as 
consistent with significant heterogeneity. To assess 
consistency across data sources, we also analysed 
coprimary outcomes by country.
We also conducted an additional analysis with an as-
treated exposure definition. For this analysis, treatment 
duration was based on the estimated number of days 
covered by filled prescriptions, allowing for up to 90 
days between prescriptions (gap period) and after the 
last prescription, which aimed to allow for irregular 
drug use and the capture of events occurring shortly 
after treatment cessation. In addition to censoring 
criteria applied in the primary analysis, patients were 
also censored at end of treatment and crossover to the 
other study drug. The serious adverse event outcomes 
were analysed with an as-treated exposure definition.
We did a preplanned sensitivity analysis of the 
Swedish part of the matched cohort with additional 
multivariable adjustment for glycated haemoglobin, 
blood pressure, estimated glomerular filtration rate, 
albuminuria, body mass index, and smoking status. 
Because these six variables all had some missing values 
(web table 6), we used multiple imputation25; using the 
PROC MI procedure in SAS, 10 datasets were imputed 
applying the Markov Chain Monte Carlo method. When 
assessing the results, we compared the estimates for 
the coprimary outcomes from this analysis with those 
from the primary analysis of the Swedish part of the 
study cohort, thus evaluating the impact of additional 
adjustment for the mentioned variables and hence the 
potential influence of these variables as unmeasured 
confounders in the main analysis.
We also conducted two post hoc sensitivity analyses. 
Firstly, we adjusted the models for country. Secondly, 
to test a shorter gap period in the operational definition 
of as-treated, we redid the analysis using 30 day and 
60 day gap periods.
Patient and public involvement
No patients were involved in setting the research 
question, or in the design, conduct, or interpretation 
of the study. Being a study based on anonymised 
nationwide register data, there is no planned 
dissemination of results directly to study participants. 
A lay summary will be published on Karolinska 
Institute’s website and a press release will be issued. 
The authors will share the results with patient advocacy 
and national cardiovascular groups.
Results
Cohort
During the study period, 25 988 eligible new 
users of SGLT2 inhibitors and 94 411 new users 
of DPP4 inhibitors were identified (fig 1; baseline 
characteristics before matching overall in web table 
7 and by country in web tables 8-10). Following 1:1 
matching by propensity score, age, sex, and history 
of major cardiovascular disease, the study cohort 
included 20 983 pairs of new users of SGLT2 inhibitors 
and DPP4 inhibitors. The groups were well balanced 
on all measured covariates (table 1); mean age was 
61 (standard deviation 10), 60% were male, 19% had 
history of major cardiovascular disease, and 6% had 
history of heart failure.
In the primary intention-to-treat analysis, duration 
of follow-up was a median 1.4 years (interquartile 
range 0.7-2.3; mean 1.5 (standard deviation 1.0)) 
overall, 1.1 years (0.6-2.0; 1.3 (0.9)) in the SGLT2 
inhibitor group, and 1.7 years (0.8-2.7; 1.8 (1.1)) in 
the DPP4 inhibitor group. Of 27 416 person years of 
follow-up in the SGLT2 inhibitor group, 22 627 (83%) 
were among patients who initiated dapagliflozin, 4521 
(16%) among those who initiated empagliflozin, and 
268 (1%) among those who initiated canagliflozin. 
The distribution of person years by individual DPP4 
inhibitors is shown in web table 11. The reasons for 
censoring according to study drug are shown in web 
table 12.
In the additional as-treated analysis, which was 
based on follow-up time from drug initiation to drug 
cessation or switch to the other study drug, the duration 
of follow-up was median 0.8 years (interquartile range 
0.4-1.5; mean 1.0 (standard deviation 0.9)) overall, 
0.7 years (0.3-1.2; 0.9 (0.7)) among SGLT2 inhibitor 
users, and 0.9 years (0.5-1.7; 1.2 (0.9)) among DPP4 
inhibitor users. The reasons for censoring according to 
study drug are shown in web table 12.
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Primary and secondary outcomes
Figure 2 shows the cumulative incidences of coprimary 
and secondary outcomes. During follow-up, 467 SGLT2 
inhibitor users (incidence rate 17.0 events per 1000 
person years) and 662 DPP4 inhibitor users (18.0) had 
a major cardiovascular event, whereas 130 (4.7) and 
265 (7.1) users had a heart failure event, respectively. 
The hazard ratios, comparing SGLT2 inhibitors with 
DPP4 inhibitors, were 0.94 (95% confidence interval 
0.84 to 1.06) for major cardiovascular events and 0.66 
(0.53 to 0.81) for heart failure (table 2).
Hazard ratios for secondary outcomes were 0.99 
(95% confidence interval 0.85 to 1.17) for myocardial 
infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 
to 1.08) for cardiovascular death, and 0.80 (0.69 to 
0.92) for any cause death (table 2). In the additional 
as-treated analysis, the hazard ratio for the major 
cardiovascular events composite outcome was 0.84 
(0.72 to 0.98), which appeared to be primarily driven 
by the cardiovascular death component (table 2). The 
hazard ratio for heart failure was 0.55 (0.42 to 0.73; 
table 2).
Subgroup analyses
Subgroup analyses are shown in figure 3. For both 
the outcome of major cardiovascular events and 
the outcome of heart failure, we saw substantial 
differences in incidence rates across subgroups, 
with the highest rates of outcome events observed 
among patients with history of major cardiovascular 
disease and those with history of heart failure. For the 
Propensity score estimation and 1:1 matching by age, sex,
history of major cardiovascular disease, and propensity score
Excluded
Dialysis or renal transplantation
End stage illness
Drug misuse
Major pancreatic disease
No prescription drug or register
  entry in national patient register
  in previous year
Hospital admission in previous
  30 days
64
180
241
313
93
876
New users of DPP4 inhibitorsNew users of SGLT2 inhibitors
Included in matched cohort
20 983   New users of SGLT2 inhibitors 20 983   New users of DPP4 inhibitors
1683
Excluded
Dialysis or renal transplantation
End stage illness
Drug misuse
Major pancreatic disease
No prescription drug or register
  entry in national patient register
  in previous year
Hospital admission in previous
  30 days
1165
1612
918
891
749
8274
41 966
12 498
27 671 106 909
New users of DPP4 inhibitors
eligible for inclusion
New users of SGLT2 inhibitors
eligible for inclusion
25 988 94 411
Fig 1 | Flowchart of patient inclusion in study cohort of new users of SGLT2 inhibitors and DPP4 inhibitors in Denmark, 
Norway, and Sweden, from April 2013 to December 2016. SGLT2=sodium-glucose cotransporter 2; DDP4=dipeptidyl 
peptidase 4. A single patient could be excluded because of more than one reason
Characteristic
SGLT2 inhibitors 
(n=20 983)
DPP4 inhibitors 
(n=20 983)
Male sex 12 589 (60) 12 589 (60)
Age, mean (standard deviation) 61 (10) 61 (10)
Country
 Sweden 9125 (43) 9125 (43)
 Denmark 5536 (26) 5536 (26)
 Norway 6322 (30) 6322 (30)
Place of birth
 Scandinavia 17 609 (84) 17 592 (84)
 Rest of Europe 1359 (6) 1389 (7)
 Outside Europe 1988 (9) 1977 (9)
 Missing 27 (<1) 25 (<1)
Civil status 
 Married/living with partner 11 857 (57) 11 789 (56)
 Single 9086 (43) 9149 (44)
 Missing 40 (<1) 45 (<1)
Education 
 Primary school/secondary school/vocational training* 11 522 (79) 11 519 (79)
 Short tertiary education 1116 (8) 1116 (8)
 Medium or long tertiary education 1704 (12) 1705 (12)
 Missing 319 (2) 321 (2)
Year of cohort entry†
 2013 1278 (6) 3872 (18)
 2014 4364 (21) 5292 (25)
 2015 6081 (29) 5884 (28)
 2016 9260 (44) 5935 (28)
Comorbidities 
 Acute coronary syndrome 1543 (7) 1578 (8)
 Other ischaemic heart disease 3648 (17) 3662 (17)
 Heart failure/cardiomyopathy 1164 (6) 1174 (6)
Table 1 | Baseline characteristics of new users of SGLT2 inhibitors and DPP4 inhibitors 
matched by propensity score, age, sex, and history of major cardiovascular disease in 
Denmark, Norway, and Sweden, from April 2013 to December 2016. Data are number 
(%) of users unless stated otherwise
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outcome of major cardiovascular events, we saw no 
significant heterogeneity in analyses of the association 
with SGLT2 inhibitors according to history of major 
cardiovascular disease and history of heart failure. 
However, we saw significant heterogeneity by sex 
and age. For the outcome of heart failure, we saw no 
significant heterogeneity across subgroups. Results by 
country are shown in web table 13.
Sensitivity analyses
The preplanned sensitivity analysis based on the 
Swedish part of the cohort was—in addition to 
confounding control through matching by propensity 
score, age, sex, and history of major cardiovascular 
disease—also adjusted for glycated haemoglobin, 
blood pressure, glomerular filtration rate, albuminuria, 
body mass index, and smoking status. Web table 6 
shows the distribution of these variables and web 
table 14 shows the estimates from the multivariable 
model with multiple imputation. Comparing SGLT2 
inhibitors with DPP4 inhibitors, hazard ratios for major 
cardiovascular events (1.04 (95% confidence interval 
0.87 to 1.24)) and heart failure (0.83 (0.61 to 1.12)) 
in these additionally adjusted analyses were similar 
to those observed in the Swedish part of the matched 
cohort without such adjustment (1.01 (0.85 to 1.21) 
and 0.77 (0.57 to 1.04), respectively).
In post hoc sensitivity analyses (web table 15), 
hazard ratios of the coprimary outcomes with 
additional adjustment for country were unchanged 
compared with the primary analyses. Hazard ratios 
of the coprimary outcomes of the as-treated analysis 
with the gap period reduced to 30 days and 60 days, 
respectively, were similar to those of the main as-
treated analysis.
Supplementary serious adverse event outcomes
The incidence rate of lower limb amputation was 
3.1 events per 1000 person years among SGLT2 
inhibitor users and 2.6 events per 1000 person years 
among DPP4 inhibitor users, whereas the rates of 
diabetic ketoacidosis were 1.4 and 0.6, respectively. 
Hazard ratios comparing SGLT2 inhibitors with DPP4 
inhibitors were 1.26 (95% confidence interval 0.88 
to 1.81) for lower limb amputation and 2.14 (1.17 to 
4.09) for diabetic ketoacidosis (web table 16).
Discussion
Main findings
This large Scandinavian cohort study investigated 
the cardiovascular effectiveness of SGLT2 inhibitors 
in routine clinical practice. Use of SGLT2 inhibitors, 
compared with use of DPP4 inhibitors, was not 
associated with a reduced risk of the coprimary 
outcome major cardiovascular events or any of 
the components of this composite outcome (the 
secondary outcomes myocardial infarction, stroke, 
and cardiovascular death). By contrast, use of SGLT2 
inhibitors was associated with a 34% reduced risk 
of the coprimary outcome heart failure and a 20% 
reduced risk of the secondary outcome any cause 
Characteristic
SGLT2 inhibitors 
(n=20 983)
DPP4 inhibitors 
(n=20 983)
 Valve disorders 473 (2) 477 (2)
 Stroke 766 (4) 745 (4)
 Other cerebrovascular disease 873 (4) 854 (4)
 Atrial fibrillation 1439 (7) 1408 (7)
 Other arrhythmia 916 (4) 833 (4)
 Coronary revascularisation in past year 284 (1) 282 (1)
 Other cardiac surgery or invasive procedure in past 
year 127 (1) 104 (<1)
 Chronic obstructive pulmonary disease 795 (4) 759 (4)
 Other lung disease 1448 (7) 1470 (7)
 Venous thromboembolism 471 (2) 447 (2)
 Cancer 1380 (7) 1406 (7)
 Liver disease 425 (2) 434 (2)
 Rheumatic disease 626 (3) 600 (3)
 Psychiatric disorder 2091 (10) 2120 (10)
 Fracture in the past year 346 (2) 344 (2)
 Arterial disease (including amputation) 1331 (6) 1273 (6)
 Renal disease 955 (5) 909 (4)
 Diabetic complications 6169 (29) 6172 (29)
Hospital admissions and outpatient visits in the past year 
 Hospital admissions due to cardiovascular causes 881 (4) 841 (4)
 Hospital admissions due to type 2 diabetes 184 (1) 180 (1)
 Hospital admissions due to other causes 2565 (12) 2559 (12)
 Outpatient visits due to cardiovascular causes 2056 (10) 1975 (9)
 Outpatient visits due to type 2 diabetes 4659 (22) 4657 (22)
 Outpatient visits due to other causes 11 780 (56) 11 655 (56)
Use of diabetes drugs in past six months 
 Metformin 16 540 (79) 16 659 (79)
 Sulphonylureas 4386 (21) 4376 (21)
 Insulin 6636 (32) 6712 (32)
 GLP1 receptor agonists 2143 (10) 2112 (10)
 Other diabetes drugs (glitazones, glinides, acarbose) 654 (3) 649 (3)
 No diabetes drug 1685 (8) 1672 (8)
Time since use of first diabetes drug (years) 
 <1 2542 (12) 2532 (12)
 1-2 2496 (12) 2559 (12)
 3-4 2528 (12) 2567 (12)
 5-6 2649 (13) 2578 (12)
 ≥7 10 768 (51) 10 747 (51)
Use other drugs in past year 
 ARB/ACE-I 13 924 (66) 13 905 (66)
 Calcium channel blocker 6250 (30) 6242 (30)
 Loop diuretic* 2114 (14) 2106 (14)
 Other diuretic* 2592 (18) 2591 (18)
 β blocker 7453 (36) 7411 (35)
 Digoxin 397 (2) 363 (2)
 Nitrate 1516 (7) 1487 (7)
 Platelet inhibitors 7643 (36) 7624 (36)
 Anticoagulant 1454 (7) 1393 (7)
 Lipid lowering drug 14 145 (67) 14 045 (67)
 Antidepressant 3261 (16) 3280 (16)
 Antipsychotic 772 (4) 794 (4)
 Anxiolytic, hypnotic, or sedative 3757 (18) 3727 (18)
 β2 agonist inhalant 2009 (10) 1951 (9)
 Anticholinergic inhalant 632 (3) 592 (3)
 Glucocorticoid inhalant 2079 (10) 2021 (10)
 Oral glucocorticoid 1522 (7) 1520 (7)
 NSAID 5415 (26) 5265 (25)
 Opioid 4098 (20) 4038 (19)
No of drugs used in past year* 
 0-5 2842 (19) 2929 (20)
 6-10 5939 (41) 5937 (40)
 11-15 3669 (25) 3596 (25)
 ≥16 2211 (15) 2199 (15)
ACE-I=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DDP4=dipeptidyl peptidase 4; 
NSAID=non-steroidal anti-inflammatory drug; SGLT2=sodium-glucose cotransporter 2; GLP1=glucagon-like peptide 1.
*Variable available in Denmark and Sweden but not Norway. Data reported for Denmark and Sweden only.
†Year of cohort entry was not included in the propensity score.
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death. Nineteen per cent of patients in the cohort had 
history of major cardiovascular disease; hazard ratios 
for the coprimary outcomes were consistent among 
subgroups of patients with and without such history.
Interpretation and comparison with previous studies
A recent meta-analysis of the three randomised 
cardiovascular outcome trials published so far 
confirmed the benefit of SGLT2 inhibitors on hospital 
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Fig 2 | Cumulative incidence of cardiovascular events associated with use of SGLT2 inhibitors, compared with use of DPP4 inhibitors—primary 
analyses (intention-to-treat exposure definition). Owing to declining numbers of patients at risk and outcome events, cumulative incidence curves 
were truncated at three years (maximum follow-up in the study was three years and nine months)
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admission for heart failure (hazard ratio 0.69 (95% 
confidence interval 0.61 to 0.79)); an effect that 
was similar in patients with (0.71 (0.62 to 0.82)) 
and without (0.64 (0.48 to 0.85)) atherosclerotic 
cardiovascular disease at baseline.4 In accordance with 
these findings, use of SGLT2 inhibitors in our study was 
associated with a risk reduction of heart failure that 
was of similar magnitude and consistent in subgroups 
of patients with and without major cardiovascular 
disease as well as those with and without pre-existing 
heart failure. This finding supports the notion that 
SGLT2 inhibitors could reduce risk of heart failure 
outcomes in a broad group of patients at varying levels 
of cardiovascular risk. However, in the light of the large 
differences in heart failure event rates between patients 
with and without history of heart failure as well as with 
and without history of cardiovascular disease, but with 
similar hazard ratios, patients with such histories are 
likely to derive the largest absolute benefit.
By contrast to our finding of no association between 
SGLT2 inhibitors and major cardiovascular events in the 
primary analysis with an intention-to-treat exposure 
definition, the meta-analysis4 showed that SGLT2 
inhibitors reduced risk of major adverse cardiovascular 
events (the composite of myocardial infarction, stroke, 
and cardiovascular death; hazard ratio 0.89 (95% 
confidence interval 0.83 to 0.96)). The protective effect 
seemed to be confined to patients with established 
atherosclerotic cardiovascular disease (0.86 (0.80 to 
0.93)) whereas patients without such disease (but who 
had multiple cardiovascular risk factors, according 
to the design of the included trials) did not benefit 
(1.00 (0.87 to 1.16)). In our study, 81% of the study 
population did not have history of major cardiovascular 
disease at baseline, although subgroup analyses of 
those with such history also showed no association 
between use of SGLT2 inhibitors and risk of major 
cardiovascular events. Importantly, 83% of the person 
years of follow-up in our study were among patients who 
initiated dapagliflozin; in the DECLARE-TIMI 58 trial of 
dapagliflozin, researchers saw no reduction of major 
adverse cardiovascular events (0.93 (0.84 to 1.03)), not 
even in patients with established cardiovascular disease 
(although the hazard ratio in that subgroup tended 
towards possible benefit; 0.90 (0.79 to 1.02)).1
A few cohort studies have assessed cardiovascular 
risks associated with SGLT2 inhibitors. A multinational 
database study (CVD-REAL)7-10 and a study based on 
US Military Health System data (EASEL)11 reported 
reduced risk of cardiovascular events and death 
associated with SGLT2 inhibitors but had study 
design limitations. An important requirement for 
entry in a new user, pharmacoepidemiological cohort 
is that individuals are free of both the study drug 
and comparator drug during a washout period before 
entry.15 At the cohort creation step in CVD-REAL and 
EASEL, the assessment of new user status of SGLT2 
inhibitor users and comparator drug users was 
separated, only taking into consideration previous 
use within the respective drug group. Further, drug 
exposure group assignment followed a hierarchical 
structure, giving preference to the SGLT2 inhibitor 
group. Hence, as outlined elsewhere,12 13 immortal 
time was introduced in patients initiating an SGLT2 
inhibitor after having used a comparator drug, 
because these patients will have survived until the 
date of SGLT2 inhibitor initiation whereas the time 
on comparator drug was not included in the analysis. 
This immortal time would bias results in a protective 
direction favouring SGLT2 inhibitors. This bias likely 
explains why the hazard ratios for any cause death in 
those studies were around 0.50, whereas in our study, 
Table 2 | Risk of coprimary and secondary outcomes associated with use of SGLT2 inhibitors, compared with use of 
DPP4 inhibitors
SGLT2 inhibitors (n=20 983) DPP4 inhibitors (n=20 983)
Hazard ratio 
(95% CI)
Absolute difference 
(No of events per 
1000 person years; 
95% CI)
No of 
events
Incidence rate  
(No of events per 
 1000 person years)
No of 
events
Incidence rate  
(No of events per  
1000 person years)
Primary analyses (intention-to-treat exposure definition)
Coprimary outcomes 
 Major cardiovascular events* 467 17.0 662 18.0 0.94 (0.84 to 1.06) −1.1 (−2.9 to 1.1)
 Heart failure† 130 4.7 265 7.1 0.66 (0.53 to 0.81) −2.4 (−3.3 to −1.3)
Secondary outcomes 
 Myocardial infarction 259 9.4 349 9.4 0.99 (0.85 to 1.17) −0.1 (−1.4 to 1.6)
 Stroke 169 6.1 238 6.4 0.94 (0.77 to 1.15) −0.4 (−1.5 to 1.0)
 Cardiovascular death 100 3.6 163 4.4 0.84 (0.65 to 1.08) −0.7 (−1.5 to 0.4)
 Any cause death 282 10.2 494 13.2 0.80 (0.69 to 0.92) −2.6 (−4.1 to −1.1)
Additional analyses (as-treated exposure definition)
Coprimary outcomes 
 Major cardiovascular events* 281 15.0 433 17.5 0.84 (0.72 to 0.98) −2.8 (−4.9 to −0.4)
 Heart failure† 73 3.9 172 6.9 0.55 (0.42 to 0.73) −3.1 (−4.0 to −1.9)
Secondary outcomes 
 Myocardial infarction 163 8.7 227 9.1 0.93 (0.76 to 1.14) −0.6 (−2.2 to 1.3)
 Stroke 98 5.2 153 6.1 0.83 (0.64 to 1.07) −1.0 (−2.2 to 0.3)
 Cardiovascular death 58 3.1 113 4.5 0.67 (0.49 to 0.93) −1.5 (−2.3 to −0.3)
 Any cause death 155 8.2 277 11.1 0.75 (0.61 to 0.91) −2.8 (−4.3 to −1.0)
SGLT2=sodium-glucose cotransporter 2; DDP4=dipeptidyl peptidase 4.
*Defined as composite of myocardial infarction, stroke, and death from cardiovascular causes.
†Defined as hospital admission for, or death due to, heart failure.
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which excluded users of either study drug before 
cohort entry, the hazard ratio was 0.80. A third study, 
based on US claims, Medicare, and Medicaid data and 
focused on heart failure alone, similarly separated the 
inclusion SGLT2 inhibitors and comparator drugs.6
In another study based on Korean data investigating 
heart failure in SGLT2 inhibitor users versus DPP4 
inhibitor users, the hazard ratio for heart failure was 
similar to that in our study.5 A well designed study 
based on US claims data compared canagliflozin 
with three individual glucose lowering drug classes, 
including DPP4 inhibitors.14 In accordance with our 
study, it reported a reduced risk of heart failure that 
was of similar magnitude in both patients with and 
without history of heart failure, whereas no reduced 
risk of cardiovascular events was observed. That study, 
however, had neither information on causes of death, 
which precluded the inclusion of cardiovascular death 
in the cardiovascular composite, nor adequate data 
on total mortality. Similarly, another well designed 
study used claims data to compare empagliflozin with 
sitagliptin; focused on the outcome of heart failure, it 
found a hazard ratio of similar magnitude as that in 
our study.26
Our study expands on previous observational 
data. Building on nationwide populations from 
three countries and adequately implementing an 
active-comparator new-user design, it provides 
the full spectrum of relevant outcomes including 
cardiovascular and any cause death for the SGLT2 
inhibitor class, mainly based on dapagliflozin. Further, 
the results are supported by the consistency of the 
estimates when taking glycated haemoglobin, blood 
pressure, glomerular filtration rate, albuminuria, body 
mass index, and smoking into account in a sensitivity 
analysis based on an entire country.
We conducted our main analyses using an intention-
to-treat exposure definition. Hence, when interpreting 
the estimates, it is important to recognise that the 
analyses explicitly aimed to include all available 
person time among patients initiating SGLT2 
inhibitors, regardless of subsequent downstream 
Major cardiovascular events
  Primary analysis
    Sex
      Female
      Male
    Age
      <65
      ≥65
    History of major cardiovascular disease
      No
      Yes
    History of heart failure
      No
      Yes
Heart failure
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    Sex
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Fig 3 | Subgroup analyses of association between use of SGLT2 inhibitors and use of DPP4 inhibitors and risk of major cardiovascular events and 
heart failure. SGLT2=sodium-glucose cotransporter 2; DDP4=dipeptidyl peptidase 4
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events, for instance, treatment cessation or switch. The 
main analyses thus investigated the overall clinical 
cardiovascular impact of initiating SGLT2 inhibitors. In 
the additional analysis with an as-treated definition of 
exposure, the magnitude of the protective association 
between SGLT2 inhibitors and both heart failure and 
any cause death became larger and a reduced risk of 
major cardiovascular events that was largely driven by 
the cardiovascular death component was observed. 
This finding indicates that the cardiovascular impact 
of SGLT2 inhibitors could be stronger during the time 
patients stay on the drug.
Our analysis of diabetic ketoacidosis, showing a 
twofold increased risk, is consistent with our previous 
study in which the comparator group was glucagon-
like peptide 1 receptor agonists and that was based 
on nationwide data from Denmark and Sweden.16 
The current study expands on those findings by using 
DPP4 inhibitors as a comparator and by including 
data from an additional country (Norway). The 
results are in line with a relatively consistent body 
of literature supporting an increased risk of diabetic 
ketoacidosis with SGLT2 inhibitors.1 16 22 23 27 Further, 
the estimate for lower limb amputation in our study 
was inconclusive (hazard ratio 1.26 (95% confidence 
interval 0.88 to 1.81)), adding to the uncertainty 
regarding this potential adverse event, with some data 
supporting an association2 16 24 28 and other data not in 
support.1 3 28 29
Limitations
Although we took meticulous care to control for 
confounding, the observational design of the study 
and the absence of randomisation means that 
residual confounding cannot be ruled out. However, if 
confounding were present, it would have to selectively 
bias the association in a protective direction for SGLT2 
inhibitors for one cardiovascular outcome (heart 
failure) but not others (eg, myocardial infarction and 
stroke).
The study period was the first four years following the 
approval of SGLT2 inhibitors for clinical use. Although 
25% of the SGLT2 inhibitor group were followed up for 
two years and more (as indicated by the upper limit 
of the interquartile range), median follow-up among 
SGLT2 inhibitor users was 1.1 years. A longer duration 
of follow-up might be required to detect differences in 
the major cardiovascular events outcome.
With patients who initiated dapagliflozin 
contributing with the majority of follow-up time in our 
study, the results mainly apply to this specific drug. 
Investigation of cardiovascular events associated with 
different individual SGLT2 inhibitors and their head-
to-head effectiveness represent important topics for 
future studies.
We chose DPP4 inhibitors as the active comparator 
because these drugs are also one of the newer glucose 
lowering drug classes, used as second line agents. 
We aimed to investigate the clinical effectiveness of 
SGLT2 inhibitors, which relies on the comparator 
group being risk neutral. With regard to the outcome 
of major cardiovascular events, all four published 
cardiovascular outcome trials of DPP4 inhibitors 
(saxagliptin, sitagliptin, alogliptin, and linagliptin) 
were neutral.30-33 With regard to heart failure, three 
of the trials were neutral and one, investigating 
saxagliptin, reported a small increase in risk,30-33 
whereas large observational studies found no increased 
risk associated with DPP4 inhibitors or with saxagliptin 
specifically.34 35 In our study, saxagliptin represented 
only 4% of DPP4 inhibitor exposure. Even if DPP4 
inhibitors were not risk neutral, the analysis would 
still reflect the head-to-head comparative effectiveness 
of SGLT2 inhibitors versus DPP4 inhibitors.
Conclusion
In this large Scandinavian cohort, use of SGLT2 
inhibitors, as compared with DPP4 inhibitors, was 
associated with reduced risk of heart failure and 
any cause death but not with major cardiovascular 
events in the primary intention-to-treat analysis. In 
the additional as-treated analyses, the magnitude 
of the association with heart failure and any cause 
death became larger, and a reduced risk of major 
cardiovascular events that was largely driven by 
the cardiovascular death component was observed. 
These data help inform patients, practitioners, and 
authorities regarding the cardiovascular effectiveness 
of SGLT2 inhibitors in routine clinical practice.
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